Single enzyme nanoparticle, an effective tool for enzyme replacement therapy.


Journal

Archives of pharmacal research
ISSN: 1976-3786
Titre abrégé: Arch Pharm Res
Pays: Korea (South)
ID NLM: 8000036

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 30 10 2019
accepted: 20 01 2020
pubmed: 29 1 2020
medline: 2 10 2020
entrez: 29 1 2020
Statut: ppublish

Résumé

The term "single enzyme nanoparticle" (SEN) refers to a chemically or biologically engineered single enzyme molecule. SENs are distinguished from conventional protein nanoparticles in that they can maintain their individual structure and enzymatic activity following modification. Furthermore, SENs exhibit enhanced properties as biopharmaceuticals, such as reduced antigenicity, and increased stability and targetability, which are attributed to the introduction of specific moieties, such as poly(ethylene glycol), carbohydrates, and antibodies. Enzyme replacement therapy (ERT) is a crucial therapeutic option for controlling enzyme-deficiency-related disorders. However, the unfavorable properties of enzymes, including immunogenicity, lack of targetability, and instability, can undermine the clinical significance of ERT. As shown in the cases of Adagen®, Revcovi®, Palynziq®, and Strensiq®, SEN can be an effective technology for overcoming these obstacles. Based on these four licensed products, we expect that additional SENs will be introduced for ERT in the near future. In this article, we review the concepts and features of SENs, as well as their preparation methods. Additionally, we summarize different types of enzyme deficiency disorders and the corresponding therapeutic enzymes. Finally, we focus on the current status of SENs in ERT by reviewing FDA-approved products.

Identifiants

pubmed: 31989476
doi: 10.1007/s12272-020-01216-3
pii: 10.1007/s12272-020-01216-3
doi:

Substances chimiques

Immunoglobulin G 0
Recombinant Fusion Proteins 0
Recombinant Proteins 0
elapegademase 9R3D3Y0UHS
Alkaline Phosphatase EC 3.1.3.1
Adenosine Deaminase EC 3.5.4.4
Phenylalanine Ammonia-Lyase EC 4.3.1.24
pegvaliase N6UAH27EUV
asfotase alfa Z633861EIM

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-21

Subventions

Organisme : Ministry of Science and ICT (KR)
ID : NRF-2018R1C1B6005379
Organisme : Ministry of Science and ICT (KR)
ID : NRF-2018M3A7B4071204

Références

Arch Virol. 2013 Nov;158(11):2365-70
pubmed: 23690054
Life Sci. 2006 Mar 27;78(18):2081-7
pubmed: 16413584
Comput Biol Chem. 2018 Aug;75:32-38
pubmed: 29734080
J Chem Inf Model. 2011 Jun 27;51(6):1431-8
pubmed: 21615159
J Chem Inf Model. 2008 Jan;48(1):42-55
pubmed: 18076152
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5964-70
pubmed: 21843936
Annu Rev Pathol. 2008;3:499-522
pubmed: 18039138
Virus Res. 2004 Jul;103(1-2):173-6
pubmed: 15163506
Antiviral Res. 2011 Sep;91(3):314-20
pubmed: 21782851
Annu Rev Med. 2013;64:189-202
pubmed: 23327522
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Jul;11(4):e1554
pubmed: 30932351
N Engl J Med. 2009 Mar 5;360(10):953-6
pubmed: 19258250
Nature. 2009 Jun 25;459(7250):1122-5
pubmed: 19516283
Microbes Infect. 2006 Apr;8(5):1287-93
pubmed: 16682242
J Virol. 2009 Oct;83(20):10366-73
pubmed: 19641000
PLoS One. 2013 May 01;8(5):e62482
pubmed: 23658730
Postgrad Med. 2009 Sep;121(5):43-7
pubmed: 19820273
J Virol. 2013 Sep;87(18):10016-24
pubmed: 23824808
Cell Microbiol. 2007 Jul;9(7):1683-94
pubmed: 17324159
Annu Rev Microbiol. 1989;43:465-501
pubmed: 2679361
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
SAR QSAR Environ Res. 2016 Dec;27(12):999-1014
pubmed: 27667445
Int Immunopharmacol. 2018 Jan;54:177-187
pubmed: 29153953
Int Immunopharmacol. 2012 Jan;12(1):294-301
pubmed: 22193241
Antiviral Res. 2012 Nov;96(2):91-9
pubmed: 22982118
Comput Biol Chem. 2017 Dec;71:207-218
pubmed: 29149637
J Chem Inf Comput Sci. 1993 Jan-Feb;33(1):79-85
pubmed: 8440755
Virology. 2015 Oct;484:305-12
pubmed: 26142497
J Food Drug Anal. 2018 Jul;26(3):1015-1023
pubmed: 29976394
FEBS J. 2013 Nov;280(22):5829-40
pubmed: 24034558
J Mol Graph Model. 2002 Jan;20(4):269-76
pubmed: 11858635
J Infect Chemother. 2003 Sep;9(3):195-200
pubmed: 14513385
Biochem Pharmacol. 2008 Feb 15;75(4):787-809
pubmed: 17900536

Auteurs

Dong Hyun Kim (DH)

College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.

Han Sol Lee (HS)

College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.

Tae-Wan Kwon (TW)

College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.

Young-Min Han (YM)

College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea.

Nae-Won Kang (NW)

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea.

Mee Yeon Lee (MY)

Department of Pharmacy, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Seoul, 07610, Republic of Korea.

Dae-Duk Kim (DD)

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea.

Myeong Gyu Kim (MG)

Graduate School of Clinical Pharmacy, CHA University, Pocheon, 11160, Republic of Korea. kimmg@cha.ac.kr.

Jae-Young Lee (JY)

College of Pharmacy, Chungnam National University, Daejeon, 34134, Republic of Korea. jaeyoung@cnu.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH